Br J Cancer. 2021 Feb 24. doi: 10.1038/s41416-021-01265-5. Online ahead of print.

ABSTRACT

Cannabis and its derivatives are being used increasingly by patients with cancer, including patients with glioblastoma multiforme (GBM), the most common and aggressive primary brain malignancy. Despite promising preclinical data suggesting potential anti-cancer effects for cannabinoids in GBM, clinical and safety data are lacking. This editorial will discuss a recent Phase 1b trial of nabiximols oromucosal spray in combination with dose-intense temozolomide in patients with recurrent GBM in the context of other relevant findings in this field.

PMID:33623077 | DOI:10.1038/s41416-021-01265-5


Source: ncbi 2

Partage le savoir
Categories: Medical

error: Content is protected !!